Glioblastoma continues to be one of the most devasting diseases, with a severe lack of options available for treatment. Between drug delivery challenges, inefficient preclinical models and post-treatment recurrence, this is one of the most difficult tumors to develop treatments for.

Returning as an in-person meeting after three years, leading experts in the field, from key decision makers in pharma and biotech to academic pioneers re-united at the 4^th Glioblastoma Drug Development Summit to celebrate successes, learn from failures and explore novel approaches in GBM drug development over the past 12 months.

With the space moving towards novel approaches such as CAR-T Therapy and RNA vaccines, using combinations to enhance existing therapies and the expansion of GBM AGILE, there is so much to unpack at the only meeting dedicated to discussing GBM research.

This focused summit facilitated discussion and collaboration from all areas of the GBM community, evaluating new ways to address key challenges associated with drug development like overcoming the blood-brain-barrier, addressing emerging resistance and securing funding for drug development projects.